- Home
- ECPG vs ARVN Comparison
ECPG vs ARVN Comparison
Compare ECPG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- ARVN
- Stock Information
- Founded
- ECPG 1998
- ARVN 2015
- Country
- ECPG United States
- ARVN United States
- Employees
- ECPG N/A
- ARVN N/A
- Industry
- ECPG Finance Companies
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ECPG Finance
- ARVN Health Care
- Exchange
- ECPG Nasdaq
- ARVN Nasdaq
- Market Cap
- ECPG 806.1M
- ARVN 614.8M
- IPO Year
- ECPG 1999
- ARVN 2018
- Fundamental
- Price
- ECPG $40.77
- ARVN $6.81
- Analyst Decision
- ECPG Strong Buy
- ARVN Buy
- Analyst Count
- ECPG 3
- ARVN 19
- Target Price
- ECPG $62.67
- ARVN $21.19
- AVG Volume (30 Days)
- ECPG 334.9K
- ARVN 3.3M
- Earning Date
- ECPG 05-07-2025
- ARVN 05-01-2025
- Dividend Yield
- ECPG N/A
- ARVN N/A
- EPS Growth
- ECPG N/A
- ARVN N/A
- EPS
- ECPG N/A
- ARVN N/A
- Revenue
- ECPG $1,380,750,000.00
- ARVN $426,900,000.00
- Revenue This Year
- ECPG $21.62
- ARVN N/A
- Revenue Next Year
- ECPG $10.12
- ARVN N/A
- P/E Ratio
- ECPG N/A
- ARVN N/A
- Revenue Growth
- ECPG 11.49
- ARVN 498.74
- 52 Week Low
- ECPG $26.45
- ARVN $5.94
- 52 Week High
- ECPG $51.77
- ARVN $37.38
- Technical
- Relative Strength Index (RSI)
- ECPG 67.68
- ARVN 36.29
- Support Level
- ECPG $32.27
- ARVN $6.23
- Resistance Level
- ECPG $36.32
- ARVN $8.00
- Average True Range (ATR)
- ECPG 1.53
- ARVN 0.58
- MACD
- ECPG 0.71
- ARVN -0.07
- Stochastic Oscillator
- ECPG 97.88
- ARVN 16.81
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.